clinical trial · NCT07004010
Evaluating the Efficacy and Safety of Embella (Deoxycholic Acid, Produced by Espad Pharmed Co.) for the Treatment of Flank Fat
Espad Pharmed·N/A·completed·n = 30
Flank FatDeoxycholic Acid Injection
brief summary
Flank region fat is a factor affecting beauty that makes people feel uncomfortable about themselves. In 2015, deoxycholic acid was approved by the American FDA for treatment of flank fat. The purpose of this study is to evaluate the efficacy and safety of deoxycholic acid injection with the brand name Embella®, manufactured by Espad Pharmed Company, for treatment of this condition. The Primary objective of this study was the proportion of participants with grade 1 or higher ("improved, much improved, very much improved") in investigator-assessed Global Aesthetic Improvement Scale (GAIS) at Week 12 Secondary objective was assessment of other efficacy parameters as well as safety of the product
started
Aug 1, 2024
primary completion
Dec 30, 2024
completion
Dec 30, 2024
last updated
Jan 21, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol